Figure 3From: Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson’s disease: an open-label studyChange from baseline to end of maintenance in PDSS-2 domain and individual item scores, FAS, LOCF.†95% CI does not contain zero (for change from baseline [i.e., before to after rotigotine add-on]). PDSS-2: Parkinson’s Disease Sleep Scale; FAS: full analysis set; LOCF: last observation carried forward.Back to article page